Ranbaxy global strategy for growth

Journal of Case Research Volume II Issue 01

Page | 1

Global Strategy for Growth: A Case of Ranbaxy Laboratories

Padmanabha Ramachandra Bhatt1

“Personally, I feel that companies who constantly innovate to provide better products and services and who can offer superior value propositions to the consumer are the ones likely to command more respect globally than others”2

Malvinder Mohan Singh, CEO and MD, Ranbaxy Laboratories Ltd

Indian pharmaceutical industry was worth of $ 8 billion in 2006 and had been growing at an

average rate of 8–9 %. The industry was highly fragmented with more than 20,000 registered

units and 30% of market was controlled by top ten companies and the rest of 70% by small

companies. The Global pharmaceutical industry was estimated at $ 600 billion in 2006. Indian

pharmaceutical industry has become more innovative and enterprising with more investment in

R&D especially since the WTO agreement was signed.

Ranbaxy Laboratories Ltd. was India’s largest pharmaceutical company with revenue of US $

260 million in the domestic market and $ 1.3 billion in the global market in 2006. In the

domestic market Ranbaxy enjoyed a share of 5.1% with nine brands in the Top 100 list in 2006.

It is one of the largest ANDA (Abbreviated New Drug Application) filers with US FDA ( United

States Food and Drug Administration). The company’s offices have spread over 49 countries

with employment of 12,000. It is one of the ten generics players in the world. Three-forth of

Ranbaxy’s revenue comes from international sales, with the US alone accounting for almost one

third. The range of products covers a wide band of therapies with a total over 5000 SKUs (Stock

Keep Units) globally.

Ranbaxy’s vision was “To become a research based international pharmaceutical company”.

1 Padmanabha Ramachandra Bhatt, Ph.D., Visiting Professor, Universiti Utara Malaysia

Email: [email protected] 2 Ranbaxy’s World, December, 2007


Page | 2

Ranbaxy Laboratories Limited

Ranbaxy was founded by Ranjit Singh and Dr. Gubax Singh in Amristsar to distribute Vitamin A

and anti-tuberculosis drugs to Japanese Pharmaceutical companies in 1937. The company set

up a manufacturing unit in Okahla in 1961, in collaboration with Lepatit, an Italian

Pharmaceutical company to produce the patented drug chlorophenicol for typhoid. Later

Ranbaxy bought the company in 1967. The company went public in 1973 to establish an Active

Pharmaceutical Ingredients (API) manufacturing plant at Mohali, Punjab. When Drug Price

Control Order (DPCO) was enacted in India in 1970, the prices of all drugs were stipulated by

the Government. As a result, the prices had fallen for all drugs. The company had then started

exporting bulk drugs (APIs) to Malaysia, Thailand, Srilanka, Middle-East and Singapore in 1975.

In Malaysia, it established a joint venture to manufacture and distribution of formulations. API

plant was set up to manufacture antibiotics/antibacterial at Taonsa in India in 1987.

Parvinder Singh (1993-1999)

Ranbaxy Pharmaceutical Ltd had remained as a small company under Bhai Mohan Singh till

1990. Parvinder Singh wrested the control of the company from his father Bhai Mohan singh in

1993. He was a doctorate in chemistry from the University of Michigan. He joined the company

to help his father in 1967. He was a visionary and a forward looking CEO. When Indian Patent

Act (1970) came into exist in India, Parvender Singh exploited the opportunities of new patent

act to manufacture formulations and generics. The act abolished the product patents for all

pharmaceutical and agricultural products and process patents were permitted for 5-7 years. He

had invested heavily in setting up a plant in Mohali to manufacture bulk drugs.

Parvinder Singh was always ahead of others in the industry. He wanted to make Ranbaxy a

global company. He adopted global strategy through acquisition in US, UK and India. He set up a

state-of-the-art Research and Development Centre at Gurgaon, India. R & D acted as an engine

of growth for the company. In the R & D Centre, he established Chemical Research,

Pharmaceutical Research, Fermentation Research, Novel Drug Delivery System (NDDS), and


Page | 3

New Drug Discovery Research (NDDR). The company focused on Urology, anti-infectives,

respiratory, anti inflammatory and metabolic disorders segments.

Bhai Mohan Singh’s initial strategy was to focus on Active Pharmaceutical Ingredients

(API).When Parvinder Singh took over the reign, the strategy was shifted to manufacture

generics which were off-patents drugs. Parvinder Singh made far reaching changes in the

company. He introduced management by self control in the company to facilitate all members

of the company to participate in the decision making process. He abandoned top-down policy

pursued by his father Bhai Mohan Singh. He set up a stretch target of sales of US $ 1 billion to

be achieved by 2004. Ranbaxy set up a joint venture with Eli Lilly with 50-50 partnership to

manufacture products of international quality in India in 1993. The joint venture manufactured

Lily’s products and marketed in India, Sri Lanka and Nepal. Ranbaxy was benefited in terms of

technology and Eli lilly got the advantage of low cost manufacturing.

Parvinder Singh looked forward to set up international business in USA, UK, and Latin American

countries. He has adopted global strategy through joint ventures and acquisition to achieve

sustainable growth. He formed a joint venture Ranbaxy Guangzhou China Ltd (RGCL) in China in

1993 and started manufacturing bulk drugs and formulations in 1995 ( see Table 7). The joint

venture manufactured antibiotics, analgesics, cardiovascular and other drugs and marketed all

over China. Later Ranbaxy has increased its stake in RGCL to 70%. Its brand cefran was the

market leader in China. It acquired Thai Pharmaceutical Company Unicher in 1995 and formed

Ranbaxy Unicher Co. Ltd (RUCL). RUCL was importing more than 50% of the products

manufactured in India. It has a strong presence in Antiinfectives, Haematinics, Cardiovasculars,

Nutritional & GI Tract segment in Thailand and India. Parvinder Singh established a global

alliance with Eli Lilly to manufacture and market cefactor in US in 1994. The joint venture

helped Eli Lilly to increase its market share of cefactor in USA whereas Ranbaxy was befitted in

acquaintance of stringent regulatory requirements of Food and Drugs Administration (FDA) in

the USA. Ranbaxy sourced cheap cefactor intermediates to Eli Lilly and Eli Lily in turn marketed

cofactor as branded product. Ranbaxy has entered the US market and operated through two


Page | 4

subsidiaries Ranbaxy Pharmaceutical Inc( RPI) and Ohm Laborataries Inc, the over the counter

drug manufacturer in 1995 ( Table 7). Ohm Laboratory had exceptional FDA approval record.

There was immense opportunity to sell generics in Europe. European market is attractive

because of aging population and high health costs forcing the goods to open the generics

market. Parvinder Singh wanted to exploit huge potential in Europe and keeping that in mind,

he set up a subsidiary namely Ranbaxy UK Ltd to sell its branded products in 1996. He acquired

another company Rima Pharmaceuticals, the semisynthetic pencillins maker to sell generics

products in Europe. His basic strategy was to keep the acquired units as profit centres which

helped Ranbaxy to keep acquired firms self sufficient. Also the acquisition process did not

adversely affect the managerial culture, openness, self motivation and positive attitude. The

acquired centre was given full responsibility of profit and loss of the company. The regional

managers were given high degree of autonomy. He had adopted three tier organizational

structures. The first tier consisted of senior managers and second tier regional managers and

the third country managers.

In 1990s, Ranbaxy’s effort was to sell formulations under its own brand name. It wanted to

move up from low-margin bulk pharmaceuticals to high margin branded formulations. The

major markets for branded generics are Russia, China and other developing countries.

However, in US and UK, Ranbaxy focused on formulations rather than branded products

because of stiff competition from other major players in branded generics.

In UK, Ranbaxy was successful to market branded formulations as it has received approval from

Medicines Control Agency (MCA) for many branded generics. Ranbaxy’s manufacturing strength

has been established in the field of process development, scaling up and commercialization of

APIs, world class generics, and branded generics. It set up world class manufacturing facilities in

seven countries viz. India, China, Ireland , Malaysia, Nigeria, US and Vietnam. In Malaysia it set

up Ranbaxy Malaysia Sdn Bhd (RMSB) as a joint venture between Ranbaxy and Malaysian

shareholders in 1984. A manufacturing unit was set up in Sungai Petani, Kedah to cater the

need of Malaysia and Singapore market. Later it has increased its stake in RNSB to 55%.


Page | 5

Ranbaxy’s Manufacturing facilities were approved and audited by international regulatory

agencies like US FDA, UK MCA, South Africa MCC, and Australia TGA.

Parvinder Singh made significant value addition to products efficacy or delivery in its NDDS

program. For example, the company made a significant improvement to ciprofloxacin, a Bayer

patented drug which cut the required dosage to once a day against several times a day as

needed for Bayer’s drug. It later out-licensed the technology to Bayer for $ 65 million and also

earned royalties on resulting sales. Ranbaxy has come up with three new chemical entities

(NCEs) in the area of asthma, urology and malaria. These were at various stages of clinical

development. One entity for malaria has entered Phase II of clinical trials. The molecule was

aimed at mainly for the under developing countries. In 2002, it had out-licensed a NCE,

codenamed RBx2258 (for treating the enlargement of the prostate gland in people above 50

years), to Germany’s Schwarz Pharma for further development and clinical trials. But Schwarz

Pharma had to abandon trials in late phase II due to a lack of desired results, measured in terms

of safety, efficacy, and superiority.

Ranbaxy’s international operations were spread over four regions viz. India and Middle East;

Europe, CSI, and Africa; Asia-Pacific and Latin America and North America. Parminder Singh set

up manufacturing facilities in each region to manufacture drugs at low cost.

The company has changed its financial year to January- December from April-March with effect

from January 1999.The company dropped those products the sales of which yielded low

margins. It rationalized the whole product portfolio in domestic and foreign market to achieve

the target of US$ 1 billion by 2004.

Devinder Singh Brar (1999-2004)

Paravinder Singh died of cancer in July 1999. Before his death, he established a strong base for

the company. Devinder Singh Brar was appointed as CEO and Managing Director by Bhai Mohan

Singh, Parvinder Singh’s 80 year old father in 1999. Bhai Mohan Singh did not consider

Paravinder Singh’s son Malvinder Mohan Singh for CEO as Malvinder Singh was very young and

did not have maturity to become CEO of the company. Bhai Mohan Singh commented after the


Page | 6

appointment of D S Brar as CEO, “Brar will ensure the professionalism inculcated in the

company by Parvinder Singh and take the company to new heights”.

D S Brar has envisioned ‘Vision Garuda’ of achieving a target revenue of US $ 5 billion by 2012,

70% of revenue should come from International business. He wanted to reiterate Ranbaxy “a

research based international pharmaceutical company”. He continued to follow the global

strategy of Parvinder Singh. His first acquisition was German generic business Bayer in 2000.

D S Brar took a major decision to pull out of its Indian joint venture with Eli Lilly. He felt that Eli

Lilly’s 50-50 partnership was no longer required for the production of the drugs in India. He

argued that Ranbaxy has come of age and could manufacture and market quality product

independently in Indian and overseas market. D S Brar found that there was a huge market

potential for anti-AIDS drugs in India. There were 3.7 million HIV positive patients in India.

Ranbaxy wanted to launch anti-AIDS drugs lamivudine, nevirapine, abacavir and indinavir in the

Indian market. The market was dominated by Cipla and GlaxoSmithcline who did aggressive

marketing for the drug. He used low cost manufacturing facilities to manufacture the anti-AIDS

drugs and sold directly to consumers to capture the market. The company entered Consumer

Healthcare which was thriving business in India. The company launched four brands viz. Revital,

Pepfiz, Garlic Pearl and Gesdyp. The business turnover of these products was Rs. 552 million in

2003.

D S Brar launched generic blockbuster antibiotic Augmentin in the U S Market in January 2002.

It has garnered a market share of only 1% against a market share of 80 % enjoyed by Geneva

Pharmaceuticals of Switzerlands and Tava of Israel. Ranbaxy Branded Products Division, a

marketing arm of Ranbaxy which marketed exclusive company owned branded products had

launched another branded generic product Sotret, the company’s brand for Isotretinoin capsule

in the U S market which has market size of US $ 540 million. Ranbaxy gained a market share of

8% for Sotret. It had also got approval from US FDA to make and sell a generic version of

Pfizer’s antifungal drug Diflucan. Its another product Ceftin accounted one third of Ranbaxy’s

total sales in U S.


Page | 7

During 2003, Ranbaxy’s business operations in the US had widened with revenue of US $ 412

million, representing 42% of the company’s global turnover. The company had obtained 24

approvals from US FDA in 2003. The company received US FDA approval for manufacture and

maketing of Isotretinoin of 30 mg strength in June 2003. This was not available to generic

players and even the originator itself. The US market for Isotretinoin was $ 6 million in 2003.

The company acquired the generics business of RPG Aventis Life Sciences in France to increase

the market in Europe.

D S Brar identified two focus areas viz. New Drug Discovery Research ( NDDR) and alliance

management as the key growth engines in R & D. He made an alignment with Geneva-based

Medicines for Malaria Venture (MMV) and developed synthetic peroxide anti-malarial drug RBx

11160. Ranbaxy Laborataries and GlaxoSmithKline Plc (GSK) have entered into collaboration for

drug discovery and clinical development covering a wide range of therapeutic areas. Ranbaxy

would be responsible for activities from optimization of lead components to generation of a

development candidate. Once a compound has been selected as development candidates, GSK

would complete the development. GSK has also got the responsibility of commercialization of

the product.

“The best companies are the best collaborators”3- Thomas & Friedman

Brian W Tempest (2004-2005)

D S Brar exit in July 2004 after completing his five year tenure and Dr. Brian W Tempest (57

years) was appointed as CEO and MD from July 05, 2004 to December 31, 2007. He was a

doctorate in Chemistry from Lancaster University. Tempest has 32 years of experience with 4-5

companies such as Glaxco Holidays, G D Searle, Becham and Fisons. He was more of a

operations person rather than a strategist and visionary. Tempest followed the path of D S Brar.

After taking over as CEO, Tempest said, “I feel immense pride and honour to lead Ranbaxy,

3 Ranbaxy World, December 2007


Page | 8

India’s truly global organization. ……Ranbaxy would endeavor to be at the forefront in delivering

the India centric advantages to the advanced and developing countries of the world”.4

Ranbaxy had signed another collaborative Research agreement with Avestha Gengraine

Technologies Pvt Ltd (Avesthagen) in the area of NDDR. Avesthagen was the first India’s

discovery based bio-technology and bioinformatics company. Dr. Patell, Founder and CEO,

Avesthagen commended on the collaboration, “Avesthagen’s vision has been to promote new

drug discovery and support and enable our Indian Pharma companies to reach and address the

needs of the people of the global markets. We are glad to partner with Ranbaxy in ths endeour

and look forward to a very fruitful relationship”5. Dr. Kasim Mookhtiar, Vice President NDDR, R

& D Ranbaxy said, “With the rapid growth of new drug discovery research at Ranbaxy,

opportunities exist for collaborative work. We are glad to avail of Avesthagen’s quality R & D

services in cutting edge technology to augment our capacity so that our current needs can be

met in a timely manner”6 The company wanted to climb up the value chain to increase

revenues from dosage forms sales. Dosage forms marketing operations are structured through

India; Europe, CIS, Africa; Asia Pacific, Latin America & Canada; North America, The Middle East.

Dr. Rasmi Barbhaiya, R & D President said “This collaboration provides an avenue to Ranbaxy to

leverage its discovery and early product development strengths and gain access to cutting edge

technologies”7.

Dr. Rashmi Barbhaiya, President, R & D who had held this position since April 15, 2002, left the

company in 2003. Dr Tempest himself took charge of R & D with separate heads for NDDR and

NDDS and generic Drugs Developments reporting to him directly. The company spent US $ 75

million in R & D in 2004, showing an increase of 43%. The sales of company was the highest in

USA (US$ 426 million) followed by BRIC countries (US$ 305 million) and Europe (US$ 192

million) in 2004 (Exhibit 1). The company invested in training and development needs of its

employees through tailor made programmes and extensive workshops. There is a formal

mechanism to reward employees for new ideas. It has launched a project called CRUSOE that

4 Business source Premier

5 Business source Premier 2004

6 Business source Premier 2004

7 ISI Emerging Market In India-Ranbaxy, 2003


Page | 9

works on improving operational efficiencies. Under this project, employee’s suggestions are not

only captured, but encouraged via contests. Brian Tempest used to spend two-three days in a

week visiting labs and talking to scientists.

By February 2004, Ranbaxy crossed US $ 1 billion in revenues. Ranbaxy was the third largest

filer of ANDAs (150) with US FDA in 2004. He focused four disease segments viz. Infection,

Urology, Inflammation/ Respiratory and Metabolic disorders in his New Chemical Entities (NCE)

pipeline. In Urology segment in India, Ranbaxy is leader and enjoyed a market share of 12.5% in

2006. Commenting on the company’s performance in Urology segment, Sanjeev I Dani, Senior

Vice President and Regional Director- Asia and CIS Ranbaxy said, “Ranbaxy has identified

Urology as a focus area and as result launched superior therapeutic options for the specialists

……. Our dedicated and well trained Urology team helps deliver prompt therapeutic solutions to

the Urologists and supporting specialists”8. During the first half of 2007, the company launched

three NDDS based formulations viz. Niftran, Eligard and Roliflo9.

With India becoming signatory to the WTO and introduction of the Patent Product regime, the

Indian market will be an attractive option for introduction of research-based products. In the

new patent regime, only strong players in terms of research and technical capabilities can

survive. Malvinder Singh, Regional Director -India Region of the company was appointed as an

additional Director of the company with effect from January 1, 2004 and number two in the

company. Tempest had lent his support to Malvinder Singh in his India business. Malvinder

Singh wanted to enhance the business in India. He has rationalized the product portfolio and

focused on speciality-oriented therapies. Expressing his delight at this development, Sanjeev

Dani, Senior Vice President & Regional Director, Asia & CIS, Ranbaxy, said, “We have

restructured our domestic operations to focus on high growth segments. Due to our strong

marketing capabilities coupled with new product successes, our performance has been buoyant

in recent years. It has culminated into rapid market share gains and now with the number one

position in the domestic market, we intend to secure this leadership position in the coming

months and years through attracting human resources & retaining talent. In-licensing and




Page | 10

launching innovative products remain our prime focus areas”10. He understood that in order to

be competitive, a company needs to be strong in the domestic market. He ensured right

doctors to be covered by sales representatives. The coverage ratio has gone up from 30% to

70%. He improved fiscal discipline in the company. Malavinder Singh who joined the company

in 1998 had worked in different projects such as Information Technology, generics, lifecycle

brands and global licensing.

Malvinder Mohan Singh (2005-2008 )

Tempest retired in June 2005 and Malvinder Mohan Singh became CEO and MD. Like his father,

Malvinder Mohan Singh also wanted to take Ranbaxy to a new height. His strategy was to focus

on US, Europe, and emerging markets. It has a market share of 42% in the developed countries

(Figure 1). Its market was growing at the rate of 31% in USA in 2006 (Figure 2). He bought a US

midsized generic company Mutual Pharmaceuticals for US $ 300 million and five other global

companies. He had taken shareholder’s approval to raise US$ 1.5 billion in equity and US $ 1.2

billion in debt. He raised another US $ 440 million through a Foreign Currency Convertible Bond

(FCCB) offering.

Malvinder Mohan Singh acquired Terapia S.A in Romania to serve the European market

efficiently and cost effectively in 2006. After the acquisition, it was renamed as Terapia-

Ranbaxy and became the largest generic player in Romania. The combine sale was US $ 80

million in 2006. On the completion of the transaction, Malvinder Singh said, “Romania now

becomes the third largest market for us in terms of revenue. We are committed to developing

our operation here as strategic hub for Europe and the CIS. We will continue to fortfy our global

presence, particularly in our key geographies”11.

Expressing his delight with progress of the company, Peter Burema, President, Global

Pharmaceutical Business, said, “Our combined market share, in terms of volume exceeds 10%.

This means that one out of every ten medicine packs being sold in Romania is currently being

10

Business source Premier 11

Ranbaxy World, December 2007


Page | 11

manufactured by Terapia Ranbaxy”12. Ranbaxy can take advantage of Terapia’s strong R&D and

manufacturing infrastructure as also their highly skilled senior management team. He acquired

another Be-Tabs of South Africa for US $ 70 million in 2006. Malvinder Singh after the

acquisition of Be-Tabs said, “The acquisition results in considerable synergies and further

strengthen Ranbaxy’s foothold in South Africa. It reinforces our position by expanding our

portfolio in a key market that is exhibiting strong growth potential. The move will help us to

provide effective disease management solutions in support of the government/s objective to

make health care affordable to a wider cross-section of the population”13. The company made

nine mergers and acquisition amounting to a value of US 450 million to expand its presence in

emerging and profitable markets such as Romania and South Africa in 2006. The company’s

return of net worth was 13.2% in 2006 (Exhibit 2). The company made an impressive

performance by increasing its sale to US $ 40.6 billion in 2006 (Exhibit 3). It made a net profit of

US $ 3.8 billion in 2006 (Exhibit 3).

Ranbaxy is vertically integrated in production and research. To strengthen the vertical

integration capabilities and fermentation capacities, it acquired Cardinal drugs, an API

manufacturer at Malanpur near Gwalior and a strategic stake of 15% in Kerbs Biotechnicals in

India and Jupital Biosciences Ltd, a company specializing in the development and manufacture

of peptitude products. Ranbaxy entered the fast growing Oncology therapeutic segment in the

NDDR agenda. It had a partnership with Zenotech Laboratory Ltd in India to strengthen

oncology therapy and bio-generics in 2007. It had marketed 11 oncology products as generic

formulations in the US and Canada. “Having worked with Zenotech for almost two years, we

believe that this investment and partnership provides a strong platform for us to leverage these

opportunities”14 Malvinder Singh said.

Malvinder Singh’s strategy was to focuss on out-licensing, in-licensing and NDDS. He out-

licensed Ranbaxy’s Statin molecule to Pharmaceutical Product Development Inc (PPD), a leading

contract research organization. PPD will have an exclusive worldwide licence to develop,

12

Ranbaxy World, December 2007 13

Ranbaxy World, December 2007 14



Page | 12

manufacture and market Ranbaxy’s Statin for the treatment of dyslipidemia, chlolestrol

lowering drugs account for $ 32.4 billion in sales for 200515. The company also received a

milestone payment from PPD Inc for the completion of the Phase I clinical studies. Ranbaxy

launched blockbuster anti-cholesteremic Simvastalin 80 mg and Pravastatin 80 mg in the US

market with a 180 days marketing exclusivity which has captured 56% market share during 180

days exclusivity period in 2006. In the post exclusivity period, the company launched 5, 10, 20,

40 mg strength of Simvastatin. The company also launched the first Atorvastatin under the

brand name Storvas in Malaysia. The success of Sotret 30 mg led to growth in the overall

prescription market share for the product from 21% to 25.5 % in 2006.

As of December 2006, Ranbaxy holds US FDA approvals for 121 ANDAs and 76 ANDAs are

pending for approvals. During 2006, Ranbaxy received 10 approvals and filed 28 ANDAs

including 1 PEPFAR (The US President’s Emergency Plan for AIDS Relief) ANDA for approval by

the US FDA. Malvinder Singh continued to focus on NDDS and in-licensing as strategic areas for

future growth of the company. NDDS has developed proprietary “platform technologies” and

contributed 9% to the turnover of Indian business. The in-licensing products were Synasma

(Doxophylline) and Trambax ( Tramadol Flash Tabs). In 2006, Ranbaxy entered into an

agreement with Senetek PLC, to purchase patents, trademarks and automated manufacturing

equipments for proprietary disposable auto-injector technology.

Global Consumer Healthcare registered a sales of US $ 35 million globally and US $ 19 million in

India. Revital is a powerful brand of Ranbaxy which has a market share of 72% in India.

Ranbaxy had a strong Internal Audit function with accreditation of ISO 9001-2000 certificate.

The Audit function is headed by Vice President who reports directly to the CEO and the Audit

Committee.

Ranbaxy set up a Global Quality Assurance team which ensures quality manufacturing process

across all locations.

15



Page | 13

“It is an encouraging sign that Indian companies today are more convinced about

their global strength of world-class quality, cutting-edge technology, cost

competitiveness and human capital”16- Malavinder singh

Malvinder Singh gave the strategic direction for the company to move from the generics to New

Drug Delivery System (NDDS) to New Drug Discovery Research (NDDR). Under NDDR mission,

he wanted to discover and develop novel therapies that meet large unmet medical needs and

transform Ranbaxy into a respected international research based pharmaceutical company.

Ranbaxy has spent Rs. 428 crore on R&D in 2007 to move up to the value chain.

Acquisition by Daiichi

Ranbaxy was facing many issues such as poor financial position, no major R&D breakthroughs,

increasing price wars and stiff competition in the generics market. In order to maintain its

growth and market position, Ranbaxy needed an influx of fresh funds and Malvinder Singh was

looking for a partner to tide over the financial and other issues.

Daiichi Sankyo, second largest and an innovator company in Japan wanted to manufacture low cost

generics because of Japan government’s new policy of helping the aging population by low cost

generic substitution for branded drugs. Daiichi lacked the low-cost expertise and looking for a low

cost generics company. They found an opportunity to buy Ranbaxy because of its low cost

production and research facilities to save on costs and drive growth (see Exhibit 4 for comparison).

In June 2008, Daiichi Sankyo acquired over 51% stake in Ranbaxy Laboratories Ltd at Rs. 737 per

share. Malvinder Singh sold out his stake of 34.8% to Daiichi Sankyo. The new entity can create

better market coverage by producing low cost manufacturing. With Ranbaxy’s pool of scientific,

technical and managerial resources and talent the new entity can enter a new orbit to chart a

higher trajectory of sustainable growth in the medium and long term in the developed and

emerging markets. The new entity is a significant milestone in the Ranbaxy’s mission of

becoming a research-based international pharmaceutical company. As the company moves into

a next level of growth it would benefit the organization, its shareholders and the employees.

The proposed transaction is also in line with Daiichi Sankyo’s goal of becoming an innovator

16



Page | 14

global company. Thus the creation of new entity would synergize to serve people globally in

terms of low cost drugs. Ranbaxy’s R&D capabilities of low cost manufacturing and Daiichi

Sankyo’s competency of innovation will provide the new entity with a sustainable, long-term

competitive advantage.


Page | 15

Exhibit 1: Sales of Ranbaxy Laboratories by Key Market-2004

Sales in US$ in Million

USA 426 Europe 192 UK 50 Germany 26 France 73 BRIC Countries 305 Brazil 31 Russia(Including Ukraine) 45 India 217 China 12

Source: Annual Report 2004

Exhibit 2: Key Parameters of Ranbaxy

EBIDTA Earnings before Interest, depreciation, Tax and Amortization PAT Profit after Tax ROCE Return on Capital Employed RONW Return on Net Worth


Particulars 2006 2005 2004

EBIDTA to Sales % 15.5 7.2 20.4 PAT to Sales % 08.5 5.0 13.1 ROCE % 13.2 5.3 29.6 RONW % 20.3 10.6 30.0 Earnings Per Share(Fully diluted) Rs. 13.2 06.9 18.7


Page | 16

Exhibit 3: Ranbaxy at a Glance Rs. billions

1999 2000 2001 2002 2003 2004 2005 2006

Results for the year

Sales 15.6 17.4 20.5 28.2 35.3 36.1 35.4 40.6

Index 1.8 2.0 2.4 3.2 4.1 4.1 2.7 3.0

Exports 7.3 8.1 10.3 18.5 24.7 24.6 23.2 27.2

Index 1.8 2.0 2.5 4.5 6.1 6.0 3.9 4.6

Gross Profit 2.6 3.2 3.9 7.3 10.1 7.2 3.2 6.1

Index 1.4 1.7 2.1 4.0 5.5 3.9 1.3 2.5

Profit before Tax 2.1 1.9 2.8 7.1 9.6 6.3 2.0 4.4

Index 1.3 1.2 1.8 4.5 6.0 4.0 1.0 2.2

Profit after tax 2.0 1.8 2.5 6.2 7.9 5.3 2.2 3.8

Index 1.5 1.4 1.9 4.6 5.9 3.9 1.2 2.0

Equity Dividend( in Rupees) 869.2 869.2 1158.9 2434.0 3156.3 3162.6 3,166.70 3,168.90

Index 3.7 3.7 4.9 10.3 13.3 13.3 6.0 6.0

Equity Dividend (%) 75 75 100 150 170 170 170.00 170.00

Earnings per share(Rs.) 17.0 15.7 21.9 28.9 42.6 28.3 5.68 9.87

Year-end Position

Gross Block+ 8.7 9.2 9.3 10.4 12.5 16.7 22.3 24.4

Index 1.9 2.0 2.0 2.3 2.7 3.6 3.0 3.30

Net Block 6.3 6.4 6.1 6.8 8.0 11.4 16.3 17.4

Index 1.7 1.8 1.7 1.8 2.2 3.1 2.8 3.00

Net Current Assets 8.2 8.3 7.5 9.6 13.3 9.5 11.3 12.6

Index 1.1 1.1 1.0 1.3 1.8 1.3 1.2 1.40

Net Worth 15.0 15.8 17.4 19.6 24.3 26.3 23.8 23.5

Index 1.8 1.9 2.1 2.4 3.0 3.2 1.8 1.80

Share Capital 1.2 1.2 1.2 1.9 1.9 1.9 1.9 1.9

Reserve & Surplus 13.8 14.7 16.2 17.7 22.5 24.4 21.9 21.6

Book value per share(Rs.) 129.3 136.6 149.8 105.71 131.1 141.4 63.84 63.05

No. of Employees 5347 5784 6424 6297 6797 7195 7,174.00 8,020.00



Page | 17

others 9%

Developed 42%

Emerging 49%

ROW

15%

India

21%

N.America

31%

Europe

33%

Figure 01: Global Market Mix 2006


Figure 02: Growth Contribution 2006



Page | 18

Exhibit 4: A comparison between Ranbaxy and Daiichi Sankyo

(US$ in billions)

Daiichi Sankyo

Ranbaxy Laboratories

Net Sales Overseas sales Research and Development Operating Income Net income Assets Return on Equity Earnings per share Number of consolidated subsidiaries Number of employees

8.2 3.3 1.5 1.4 0.9

13.9 7.8%

$ 1.26

43 15,349

1.0 0.6 0.1 0.2 0.1 0.5

28.8% $ 0.35

18

8,141

Source: Business World, June 13, 2008


Page | 19

Exhibit 5: Discovery Process and Stages of Drug Development

DISCOVERY PROCESS Period: upto 6 yrs Cost: Roughly $ 60 million Odds of drug reaching market: 1: 10,000 Identifying & validating targets: this involves developing the concept of how a new drug can treat a disease. Compound that should be pursued further are short listed. Screening: compound that have desirable potencies and that react encouragingly are pulled out. These are the ‘Hits’, converting Hits into ‘Leads’ calls for further refinement in the compound, during which solubility, toxicity (quality of safe doses), absorbtion, metabolism etc, are tested even as the potency and activity are maintained. STAGES OF DRUG DEVELOPMENT Period: upto 12 years Cost: upto $200-250 million Odds of drug reaching market: 1:200 Pre-clinical trials: toxicity and pharmacokinetics (absorption, distribution, metabolism, elimination) are observed via tests in labs and in animals. IND FILING: Company files an application for an investigational new drug (IND) with the FDA. This filing includes results of pre-clinical trials and the plan for human clinical trials. PHASE 1 TRIALS: Conducted on 20-100 healthy volunteers to prove safety. Once molecules enters clinical trials, odds of success drop to 1:5 PHASE 2 TRIALS: 100-300 persons suffering from the disease are treated. Considered by many companies as the stage to opt for licensing agreement. PHASE 3 TRIALS: involves between 1,000 to 5,000 patients in a bid to verify previous trials. NEW DRUG APPROVAL FILING: FDA reviews information, and if satisfied gives its approval. If it feels molecules isn’t yet ready for market, may call for phase 4 trails. POST-MARKETING SURVEYS: Companies have to conduct continuous surveillance once drug hits market, all through the life of the drug. Serious reactions can result in drug withdrawal. Sales and marketing cost can take the entire cost of exercise right from drug discovery to development to as much as $450 million.


Page | 20

Source: BUSINESS TODAY Ocotber 13 2002.

Exhibit 6: Ranbaxy Laboratories in Historical Perspectives

YEAR DESCRIPTION

1961 Company Incorporated

1973 Ranbaxy goes public

A multipurpose chemical plant is setup for the manufacture of APIs at Mohali in India

1977 Ranbaxy’s first joint venture in Lagos (Nigeria) is setup

1983 A modern dosage forms facility at Dewas (MP) in India goes on stream

1985 Ranbaxy Research Foundation is established

Stancare, Ranbaxy’s second pharmaceutical marketing division, starts functioning

1987 Production start-up at the modern APIs plant at Toansa (Punjab), makes Ranbaxy the country’s largest manufacturer of antibiotics/antibacterials

1988 Ranbaxy’s Toansa plant gets US FDA approval

1990 Ranbaxy is granted US patent for Doxycyline

1991 New state-of-the-art facility for Cephalosporins set up at Mohali

US patent granted for Cephalosporins

1992 Company enters into an agreement with Eli Lilly & Co of USA for setting up a joint venture in India to market select Lilly products

1993 Company enters into an agreement to setup a joint venture in China Ranbaxy (Guangzhou China) Limited

Ranbaxy enunciates its corporate mission ‘to become a Research based International Pharmaceutical Company

1994 The new Research Centre at Gurgaon,(near Delhi), becomes fully operational

Established Regional Headquarters in London (UK) and Raleigh (USA)

The Fermentation pilot plant at Paonte Sahib is commissioned

Ranbaxy’s GDR listed in Luxembourgh Stock Exchange

1995 Acquisition of Ohm Laboratories, a manufacturing facility in the US. Inauguration of FDA approved, state-of-the-art new manufacturing wing, at Ranbaxy’s US subsidiary Ohm Laboratories Inc.

1997 Ranbaxy Laboratories Limited crosses a sales turnover of Rs. 10,000 million, with its exports reaching an all time high of Rs. 5,000 million


Page | 21

1998 Ranbaxy enters USA, world’s largest pharmaceutical market, with products under its own name.

Ranbaxy filed its first Investigational New Drug (IND) application with the Drugs Controller General of India (DCGI) for approval to conduct Phase I clinical trials

1999 DCGI grants approval to conduct phase I clinical trials for RBx-2258, and the trials commence from June 10, 1999

Bayer AG, Germany and Ranbaxy sign an agreement where Bayer obtains exclusive development and worldwide marketing rights to an oral once daily formulation of Ciprofloxacin, originally developed by Ranbaxy.

2000 Ranbaxy files IND application for Asthma Molecule RBx-7796 after successful completion of preclinical studies.

Ranbaxy acquires Bayer’s Generics business (trading under the name of Basics) in Germany

Ranbaxy forays into Brazil, the largest pharmaceutical market in South America and achieves global sales of US $ 2.5 million in this market

2001 Ranbaxy took a significant step forward in Vietnam by initiating the setting up of a new manufacturing facility with an investment of US $ 10 million

Ranbaxy achieved a turnover of US $ 600 million for the year 2001 and moved closer to achieving the target of 1 billion dollar by 2004.

Ranbaxy USA crosses sales of US $ 100 million, fastest growing company in the US

2002 Ranbaxy files IND for an Anti-bacterial Oxazolidine-RBx-7644

Ranbaxy launched Cefuroxime Axetil post approval from USFDA for 125mg, 250mg, 500mg Tablet, first approval granted to any generic company for this product

Ranbaxy receives permission from DCGI to conduct Phase-I clinical trials for RBx 7796 (Anti-Asthma)


Page | 22

2003 Ranbaxy receives The Economic Times Award for Corporate Excellence for ‘The company of the year 2002-03’

Ranbaxy and Glaxo SmithKline Plc (GSK) accelerate their discovery programmes through a global alliance for drug discovery and development. While Ranbaxy will leverage its early product development strengths, Glaxo would use its expertise at late development stage to complete the development process

RBx 7796, Ranbaxy’s first NCE in the respiratory segment successfully completes Phase I clinical trials and steps into Phase II.

Ranbaxy files an IND application for RBx 9001, its second NCE for the treatment of Benign Prostatic Hyperplasia (BPH)

Cipro XR 500mg and 1g, based on the techonogy developed by Ranbaxy, were launched in USA by Bayer AG

Ranbaxy launched the first branded product Sotret (isotretinoin) for 10mg, 20mg and 40mg capsules in USA

2004 Ranbaxy acquired the generics business of RPG Aventies Life Sciences in France to enter European Market

2005 Ranbaxy acquired 18 generic drugs from Spain’s Eframes for sale the local market

2006 Ranbaxy’s US arm buys patents, trademarks, and automated manufacturing equipment from Senetek for its disposable autoinjector for self-administration of parental drugs for anaphylactic shock

Ranbaxy’s Italian subsidiary acquires the unbranded generic business of Allen, a division of GlaxoSmithKline, to complement its own pipeline for the Italian Market.

Buys 96.7% of Romanian drug maker Terapia from Advent International for $324 million. Combined with Ranbaxy’s own operation in Romania, the Terapia acquisition creates Romania’s largest generic firm

Aquires genrics company, Ethimed, atop 10 player in Belgium. Provide Ranbaxy a base from where to manage and expand its operations in the Benelux countries

Ranbaxy’s Spanish subsidiary purchases the Mundogen generics business of GlaxoSmithKiline in Spain. The acquisition beefs up Ranbaxy’s product portfolio in the country.

2008 Daiichi Sankyo acquired over 51% stake in Ranbaxy Laboratories Ltd at Rs. 737 per share. Malvinder Singh sold out his stake of 34.8% to Daiichi Sankyo.

Source: www.ranbaxy.com/history_ranbaxy.htm Business Today, September 10, 2006

http://www.ranbaxy.com/history_ranbaxy.htm

Copyright of Journal of Case Research is the property of XIMB - Center of Case Research and its content may

not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written

permission. However, users may print, download, or email articles for individual use.

Documents

Ranbaxy global strategy for growth